Asia Pacific Articaine Hydrochloride market is anticipated to grow at 8.43% CAGR from 2018 to 2023 and it is estimated that the Asia Pacific market was valued at USD 0.17 billion in 2018 and is expected to reach USD 0.26 billion by 2023.
Articaine is a form of an amide local anesthetic that is most commonly used in dentistry. This drug is originally known as carticaine. It has a different molecular structure with a thiophene ring instead of the usual benzene ring present in the other amide anesthetic drugs.
Articaine hydrochloride is an amide local anesthetic which has its major applications in dentistry. Increasing incidence of dental disorders is creating huge scope for the dentists resulting high revenue. The number of patients approaching the dentists is soaring as a result the pressure on the articaine hydrochloride market is rising rapidly resulting in the improvement in the effectiveness of the articaine. In oral surgeries, the use of articaine hydrochloride is the first preference for professionals due to its quicker effect. It is associated with less number of failures and also provides anesthesia in cases where other anesthetics fail.
The Asia Pacific Articaine Hydrochloride market is segmented on the basis of Application and End User. On the basis of Application, the market is segmented into Infiltration, Nerve Block, and Others. In 2018, the nerve block sub segment was the market leader. On the basis of End User, the market is segmented into Dental Clinics, Hospitals and Academic and Research Institutes. Dental Clinic held the largest share of the end user segment.
On the basis of geography, the Articaine Hydrochloride market can be segmented into various regions namely India, China, Japan, Australia and South Korea. Asia Pacific is expected to witness the highest CAGR in the coming years.
The market is dominated by companies like 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U, Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc, Pierrel S.p.A, Sanofi, Septodont, Siegfried AG, and Sigma Aldrich.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Infiltration
5.1.3 Nerve Block
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Application
5.1.6 Market Attractiveness Analysis, By Application
5.1.7 Market Share Analysis, By Application
5.2 End User
5.2.1 Introduction
5.2.2 Dental Clinics
5.2.3 Hospitals
5.2.4 Academic and Research Institutes
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 3M
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Anhui BBCA Pharmaceutical Co.Ltd.
8.3 Dentsply Sirona
8.4 Inibsa Dental S.L.U
8.5 Jinan Chenghui Shuangda Chemical Co.Ltd
8.6 Jinan Ruixing Pharmaceutical Technology Co.Ltd
8.7 Manus Aktteva Biopharma LLP
8.8 Pfizer Inc
8.9 Pierrel S.p.A
8.10 Sanofi
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
